ClinicalTrials.gg
CompletedNCT02579603Updated Feb 13, 2018Results posted

Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF

A Phase 4 interventional study of Nintedanib and Pirfenidone in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 23 sites in 6 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-02-13.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.

Enrollment
5th of 16
105 · median 49
Started
2015
the only one that year
Phase 4
5 of 16
none open now
Registered
4th of 16
by date
Lead sponsor
6 of 16
Boehringer Ingelheim

Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one is the 5th largest by enrollment, is the only one that started in 2015, is one of 5 in phase 4, and was the 4th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

This is a phase IV, twelve week, open label, randomized, parallel group study to assess safety and tolerability of combined treatment with nintedanib and pirfenidone.

A secondary objective is to assess the exposure based on PK trough concentration values to nintedanib either given alone or in combination with pirfenidone and to assess the exposure of pirfenidone when combined with nintedanib.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written consistent with ICH-GCP(The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use- Good clinical practice) and local laws, signed prior to any study procedures being performed (including any required )
  • Male or female patients aged greater than or equal to 40 years at visit 1
  • Idiopathic Pulmonary Fibrosis (IPF) diagnosis, based upon the ATS (American Thoracic Society)/ERS (European Respiratory Society)/JRS (Japanese Respiratory Society)/ALAT (Latin American Thoracic Association) 2011 guideline and confirmed by the investigator based on chest high resolution computed tomography (HRCT) scan performed within 12 months of visit 1
  • FVC (Forced vital capacity) greater than or equal to 50% of predicted normal at visit 1

Exclusion criteria

Exclusion criteria:

  • (Alanine transaminase), AST (Aspartate aminotransferase)> 1.5 fold (ULN) at visit 1
  • Total > 1.5 fold ULN at visit 1
  • Relevant airways obstruction (i.e. pre-bronchodilator (Forced Expiratory Volume in one second)/FVC \<0.7) at visit 1
  • History of myocardial infarction within 6 months of visit 1 or unstable angina within 1 month of visit 1
  • Bleeding Risk: Known genetic predisposition to bleeding, Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, dabigatran, heparin, hirudin etc) or high dose antiplatelet therapy, History of haemorrhagic central nervous system event within 12 months prior to visit 1, History of haemoptysis or haematuria, active gastro-intestinal bleeding or ulcers and/or major injury or surgery within 3 months prior to visit 1, (INR) > 2 at visit 1, Prothrombin time and partial thromboplastin time (PTT) > 150% of institutional ULN at visit 1
  • Planned major surgery during the trial participation, including lung transplantation,major abdominal or major intestinal surgery.
  • History of thrombotic event (including stroke and ) within 12 months of visit 1
  • Severe renal impairment ( \<30 mL/min calculated by Cockcroft-Gault formula at visit 1) or end-stage renal disease requiring dialysis
  • Treatment with NAC (n-acetylcysteine), prednisone >15 mg daily or >30 mg every 2 days OR equivalent dose of other oral and/or fluvoxamine within 2 weeks of visit 2
  • Treatment with azathioprine, cyclophosphamide, cyclosporine as well as any other drug within 8 weeks of visit 2
  • Previous treatment with pirfenidone
  • Permanent discontinuation of nintedanib in the past due to Adverse Events considered drug-related
  • Known to nintedanib, pirfenidone, peanut or soya or to any of the
  • A disease or condition which in the opinion of the investigator may interfere with testing procedures or put the patient at risk when participating in this trial
  • Alcohol or drug abuse which in the opinion of the treating physician would interfere with treatment
  • Women who are pregnant, nursing, or who plan to become pregnant while in the trial
  • Women of not willing or able to use highly effective methods of per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly5 for 28 days prior to and 3 months after nintedanib administration
  • Patients not able to understand and follow study procedures including completion of self administered questionnaires without help
  • Patients who require dose reduction and/or temporary interruption during the run-in period with nintedanib 150 mg bid
  • Patients with underlying chronic liver disease ( A, B or C hepatic impairment)
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Nintedanib

    Nintedanib 150 mg bid

    Drug: Nintedanib

  • Experimental
    Nintedanib and Pirfenidone

    Nintedanib 150 mg bid combined with pirfenidone up to 801 mg tid

    Drug: Nintedanib · Drug: Pirfenidone

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Patients With On-treatment Gastrointestinal (GI) AEs (SOC GI Disorders) From Baseline to Week 12

    Percentage of patients with on-treatment gastrointestinal (GI) Adverse events (AEs) (SOC GI disorders) from baseline to week 12. On-treatment AEs were defined as AEs with an onset from the first dose of randomised treatment up to the last dose of randomised treatment (inclusive).

    Time frame: Baseline to week 12

Secondary outcomes

  1. Predose Plasma Concentrations at Steady State (Cpre,ss) of Nintedanib at Baseline, Weeks 2 and 4

    Predose plasma concentrations at steady state (Cpre,ss) of nintedanib at baseline (Visit 3), Week 2 (Visit 4) and Week 4 (Visit 5)

    Time frame: baseline, prior to intake of study medication on week 2 and week 4

  2. Predose Plasma Concentrations at Steady State (Cpre,ss) of Pirfenidone

    Predose plasma concentrations at steady state (Cpre,ss) of pirfenidone at Week 2 (Visit 4) and Week 4 (Visit 5)

    Time frame: Prior to intake of study medication on week 2 and week 4

07

Results

Posted Feb 13, 2018

Participant flow

Participant flow — Overall Study
MilestoneNintedanibNintedanib + Pirfenidone
Started5253
Number of patients treated5153
Completed4851
Not completed42
Withdrew: Not treated10
Withdrew: Adverse event22
Withdrew: Other than stated10

Outcome measures

PrimaryPercentage of Patients With On-treatment Gastrointestinal (GI) AEs (SOC GI Disorders) From Baseline to Week 12

Percentage of patients with on-treatment gastrointestinal (GI) Adverse events (AEs) (SOC GI disorders) from baseline to week 12. On-treatment AEs were defined as AEs with an onset from the first dose of randomised treatment up to the last dose of randomised treatment (inclusive).

Time frame:
Baseline to week 12
Reported as:
Number · percentage of participants
Percentage of Patients With On-treatment Gastrointestinal (GI) AEs (SOC GI Disorders) From Baseline to Week 12
percentage of participantsNintedanibNintedanib + Pirfenidone
Percentage of Patients With On-treatment Gastrointestinal (GI) AEs (SOC GI Disorders) From Baseline to Week 1252.969.8
SecondaryPredose Plasma Concentrations at Steady State (Cpre,ss) of Nintedanib at Baseline, Weeks 2 and 4

Predose plasma concentrations at steady state (Cpre,ss) of nintedanib at baseline (Visit 3), Week 2 (Visit 4) and Week 4 (Visit 5)

Time frame:
baseline, prior to intake of study medication on week 2 and week 4
Reported as:
Geometric mean · ng/mL
Predose Plasma Concentrations at Steady State (Cpre,ss) of Nintedanib at Baseline, Weeks 2 and 4
ng/mLNintedanibNintedanib + Pirfenidone
baseline7.08 ± 56.07.65 ± 72.5
Week 27.25 ± 52.78.17 ± 69.8
Week 45.92 ± 73.57.13 ± 63.9
SecondaryPredose Plasma Concentrations at Steady State (Cpre,ss) of Pirfenidone

Predose plasma concentrations at steady state (Cpre,ss) of pirfenidone at Week 2 (Visit 4) and Week 4 (Visit 5)

Time frame:
Prior to intake of study medication on week 2 and week 4
Reported as:
Geometric mean · ng/mL
Predose Plasma Concentrations at Steady State (Cpre,ss) of Pirfenidone
ng/mLNintedanib + Pirfenidone
Week 21120 ± 122
Week 41220 ± 90.7

Adverse events

Collected over From first dose administration of the study medication to 28 days after last drug administration; up to 124 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib—5/51 (9.8%)36/51 (70.6%)
Nintedanib + Pirfenidone—2/53 (3.8%)46/53 (86.8%)
Most frequent serious events
Most frequent serious events
EventNintedanibNintedanib + Pirfenidone
Atrial flutterCardiac disorders1/510/53
Pancreatitis acuteGastrointestinal disorders1/510/53
Transient ischaemic attackNervous system disorders1/510/53
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/510/53
PhlebitisVascular disorders1/510/53
PneumoniaInfections and infestations0/511/53
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders0/511/53
Circulatory collapseVascular disorders0/511/53
Most frequent other events
Showing 10 of 26
Most frequent other events
EventNintedanibNintedanib + Pirfenidone
NauseaGastrointestinal disorders6/5122/53
DiarrhoeaGastrointestinal disorders16/5120/53
VomitingGastrointestinal disorders6/5115/53
FatigueGeneral disorders6/5110/53
DyspnoeaRespiratory, thoracic and mediastinal disorders8/512/53
Abdominal pain upperGastrointestinal disorders4/517/53
HeadacheNervous system disorders1/517/53
Decreased appetiteMetabolism and nutrition disorders5/516/53
BronchitisInfections and infestations2/515/53
Abdominal discomfortGastrointestinal disorders0/514/53

Baseline characteristics

Treated Set : The treated set (104 patients) consisted of all randomised patients who were dispensed study medication and were documented to have taken at least 1 dose of randomised investigational treatment.

Age, Continuous
Age, Continuous(Years)NintedanibNintedanib + PirfenidoneTotal
Mean68.9 ± 6.868.9 ± 6.668.9 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)NintedanibNintedanib + PirfenidoneTotal
Female71118
Male444286
08

Study locations

23 sites
  • Western CT Medical Group, P.C.
    Danbury, Connecticut 06810, United States
  • Tulane University Hospital and Clinic
    New Orleans, Louisiana 70112, United States
  • Minnesota Lung Center
    Minneapolis, Minnesota 55407, United States
  • The Lung Research Center, LLC
    Chesterfield, Missouri 63017, United States
  • Lowcountry Lung and Crit Care
    Charleston, South Carolina 29406, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232-5735, United States
  • St. Paul's Hospital
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Concordia Hospital
    Winnipeg, Manitoba R2K 3S8, Canada
  • HOP Avicenne
    Bobigny, 93009, France
  • HOP de la Cavale Blanche
    Brest, 29609, France
  • HOP Louis Pradel
    Bron cedex, 69677, France
  • HOP Calmette
    Lille, 59037, France
  • HOP Pasteur
    Nice, 06001, France
  • HOP Bichat
    Paris, 75018, France
  • HOP Pontchaillou
    Rennes, 35033, France
  • Klinik Donaustauf
    Donaustauf, 93093, Germany
  • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
    Essen, 45239, Germany
  • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
    Heidelberg, 69126, Germany
  • A.O.U. Policlinico Vittorio Emanuele
    Catania, 95124, Italy
  • Osp. S. Giuseppe Fatebenefratelli
    Milano, 20123, Italy
  • A.O.U. Senese Policlinico Santa Maria alle Scotte
    Siena, 53100, Italy
  • Sint Antonius Ziekenhuis
    Nieuwegein, 3435 CM, Netherlands
  • Erasmus Medisch Centrum
    Rotterdam, 3015 CE, Netherlands
09

References and documents

Publications

  • Vancheri C, Kreuter M, Richeldi L, Ryerson CJ, Valeyre D, Grutters JC, Wiebe S, Stansen W, Quaresma M, Stowasser S, Wuyts WA; INJOURNEY Trial Investigators. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. Am J Respir Crit Care Med. 2018 Feb 1;197(3):356-363. doi: 10.1164/rccm.201706-1301OC. PubMed 28889759 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Jan 2017, 14 months.

Results were first posted in Feb 2018, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2015
First posted
Oct 19, 2015
StartActual
Oct 16, 2015
Primary completionActual
Jan 3, 2017
CompletionActual
Jan 31, 2017
Results first posted
Feb 13, 2018
Last update
Feb 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02579603
Responsible party
Sponsor
First posted
Oct 19, 2015
Start date
Oct 16, 2015
Primary completion
Jan 3, 2017
Completion
Jan 31, 2017
Results posted
Feb 13, 2018
Last update
Feb 13, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion